

**AMENDMENTS TO THE CLAIMS:**

The listing of claims will replace all prior versions, and listings of claims in the application:

**LISTING OF CLAIMS:**

**Claims 1 to 18 (canceled)**

**Claim 19 (canceled)**

**Claim 20 (currently amended)** The axon sprouting stimulation kit of claim 22 claim 19, wherein C3 is selected from the group consisting of ADP-ribosyl transferase C3 derived from Clostridium botulinum, ~~a C3 polypeptide having an insertion in one or more amino acids and retaining ADP-ribosylation activity, a C3 polypeptide having a substitution in one or more amino acids and retaining ADP-ribosylation activity, a C3 fragment retaining ADP-ribosylation activity and a recombinant C3 retaining ADP-ribosylation activity.~~

**Claim 21 (canceled)**

**Claim 22 (currently amended)** An axon sprouting stimulation kit comprising

- a first container comprising a first fibrin matrix forming element,  
- a second container comprising a second fibrin matrix forming element,  
- a mixing means for intermingling said first and second fibrin matrix forming elements  
into a therapeutically acceptable fibrin matrix, and;  
- a delivery means,

~~The axon sprouting stimulation kit of claim 19, wherein one of said first or second fibrin matrix forming element is fibrinogen and the other of said first or second fibrin matrix forming element is thrombin, and wherein at least one of said first and second container comprises calcium chloride and wherein at least one of said first and second container further comprises a matrix-releasable therapeutically active agent selected from the group consisting of C3 and Y-27632 for facilitating axon sprouting at a nerve lesion site.~~

**Claims 23-24 (canceled)**

**Claim 25 (currently amended)** The axon sprouting stimulation kit of claim 22 or 37 claim 19, further comprising a protease inhibitor.

**Claims 26-27 (canceled)**

**Claim 28 (currently amended)** The axon sprouting stimulation kit of claim 25 claim 27, wherein said plasmin protease inhibitor is aprotinin.

**Claims 29-34 (canceled)**

**Claim 35 (currently amended)** The axon sprouting stimulation kit of claim 37 claim 34, wherein C3 is selected from the group consisting of ADP-ribosyl transferase C3 derived from Clostridium botulinum, a C3 polypeptide having an insertion in one or more amino acids and retaining ADP-ribosylation activity, a C3 polypeptide having a substitution in one or more amino acids and retaining ADP-ribosylation activity, a C3 fragment retaining ADP-ribosylation activity and a recombinant C3 retaining ADP-ribosylation activity.

**Claim 36 (canceled)**

**Claim 37 (currently amended)** An axon sprouting stimulation kit comprising

- a first container comprising a first fibrin matrix forming element,
- a second container comprising a second fibrin matrix forming element,
- a third container comprising a therapeutically active agent selected from the group consisting of C3 and Y-27632 for facilitating axon sprouting at said lesion site,
- a mixing means for intermingling the content of said first, second and third container to form a therapeutically acceptable fibrin matrix containing a therapeutically active agent, and;
- a delivery means,

The axon sprouting stimulation kit of claim 34, wherein one of said first or second fibrin matrix forming element is fibrinogen and the other of said first or second fibrin matrix forming element is thrombin and wherein at least one of said first, and second or third container comprises calcium chloride and wherein said therapeutically active agent is releasable from said therapeutically acceptable fibrin matrix into an adjacent external environment.

**Claim 38 (currently amended)** A biocompatible composition for facilitating axon sprouting, said composition comprising: (i) a therapeutically active agent selected from the group consisting of C3, Y-30141 and Y-27632 for facilitating axon sprouting, and (ii) a

fibrin matrix forming element selected from the group consisting of fibrinogen, thrombin and combination thereof.

**Claim 39 (canceled)**

**Claim 40 (currently amended)** The biocompatible composition of claim 38 claim 39, further comprising calcium chloride and wherein said component is thrombin.

**Claim 41 (currently amended)** The biocompatible composition of claim 38, wherein C3 is selected from the group consisting of ADP-ribosyl transferase C3 derived from Clostridium botulinum, a C3 polypeptide having an insertion in one or more amino acids and retaining ADP-ribosylation activity, a C3 polypeptide having a substitution in one or more amino acids and retaining ADP-ribosylation activity, a C3 fragment retaining ADP-ribosylation activity and a recombinant C3 retaining ADP-ribosylation activity.

**Claims 42-52 (Canceled)**